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ObituaryStephen F. Heinemann (1939–2014)Stephen F. HeinemannSteve Heinemann, one of the fathers
of modern molecular neuroscience and
a pioneer in neurotransmitter receptor
biology, passed away on August 6, 2014,
in La Jolla, California. Steve was well
known in the neuroscience community
as a genuinely nice guy with an unortho-
dox approach to research. For almost
four decades in an extraordinarily pro-
ductive career he helped to drive a quan-
tum leap forward in elucidating the
molecular components and cellular basis
of excitatory neurotransmission in the
mammalian CNS. These efforts paved
the way for new insights into funda-
mental aspects of nervous system func-
tion, which led to advances in our under-
standing of neurological and psychiatric
disorders.
Born in Boston in 1939, Stephen Fox
Heinemann obtained a bachelor in sci-
ence degree from the California Institute
of Technology in 1962. He pursued his
PhD in biochemistry at Harvard Univer-
sity in 1967 under the mentorship of
Matthew Meselson, where he studied
the structure of DNA. His postdoctoral
training was carried out at the Massa-
chusetts Institute of Technology and
Stanford University School of Medicine,
during which time he made contributions
to the understanding of the genetics of
the bacteriophage lambda life cycle.
Soon after, his interest shifted to the ner-
vous system, and he joined the Salk
Institute for Biological Studies in 1970,
where he became one of the founders
of the Molecular Neurobiology Labora-
tory at the newly minted research insti-
tute that would become his second
home. The Salk Institute, a masterpiece
of Louis Kahn, one of the most influential
architects of the 20th century, was desig-
nated a historical landmark in 1991,
following his father’s ‘‘even a brick wants
to be something’’ prophecy. A similar
destiny was to be followed by the Molec-
ular Neurobiology Laboratory, a program
to be ranked number one in world neuro-
science in the late 1980s, in part due to
discoveries arising from the Heinemann
laboratory.
In his early days at the Salk Institute,
Steve focused on the neurotransmitterreceptors present at the neuromuscular
junction. This was the model system
widely used to understand synaptic
transmission before brain synapses
became tractable. His landmark early
work, in collaboration with Jon Lind-
strom and others, established that
myasthenia gravis, a disease that leads
to muscle weakness, fatigue, and paral-
ysis, is the consequence of the presence
of autoantibodies to nicotinic acetylcho-
line receptors (nAChRs) present at the
neuromuscular junction. Steve’s primary
interest, however, was to understand
the structure and properties of these
acetylcholine receptors. In 1970, Jean-
Pierre Changeux and coworkers used
biochemical methods to characterize
the nAChR as a ligand-gated ion channel
formed by five homologous subunit pro-
teins. In order to isolate DNA comple-
mentary to the mRNA encoding specific
receptor subunit proteins, Steve decided
to use a strategy based on recently
developed molecular cloning methods.
Biochemical methods had previously
yielded short stretches of amino acid
sequences from one of the muscle
nAChR proteins; using this information,
one could clone the full-length sequenceNeuronencoding channel subunits from a suit-
able library of cDNAs. He was on the
right path, but just not on time, because
in 1982 a research group led by Shosaku
Numa cloned the first cDNA encoding a
nAChR subunit from the electric organ
of the ray Torpedo californica. Having
just lost a battle, but not the war, Steve
turned his attention to brain ligand-gated
ion channels together with Jim Boulter
and Jim Patrick. The scarcity of the
nAChR protein in the brain precluded
biochemical derivation of partial peptide
sequences, however, and a different tac-
tic was required. Relying on the assump-
tion that neuronal nAChRs should have
some degree of identity with receptor
subunits present at the neuromuscular
junction, and using low-stringency
molecular hybridization techniques, the
Heinemann group was able to clone
the first neuronal nicotinic receptor sub-
unit, which is now named a3. This
was followed by the cloning of the entire
family of neuronal nicotinic receptor a
and b subunits, the characterization
of channel properties when expressed
in heterologous systems, and the
differential distribution of receptor sub-
units in the brain. Finally, in 1994 the
a9 nicotinic cholinergic receptor was
cloned in the Heinemann laboratory,
deciphering the molecular identity of
the cholinergic receptor that mediates
efferent inhibition of sound amplification
within the inner ear. The nicotinic recep-
tor subunit clones were immediately
licensed to the pharma industry for
the development of drugs to be used
in neurological disorders and tobacco
addiction.
As increasing numbers of nicotinic
and the structurally related GABA recep-
tor subunit cDNAs began to yield to
maturing techniques in molecular neuro-
science, a new set of targets became
the object of a feverish cloning race be-
tween several laboratories, including
that of Steve Heinemann, in the late
1980s and early 1990s. These receptors
were, of course, those that mediated
excitatory signaling in the CNS, the iono-
tropic glutamate receptors (iGluRs). The
excitement about glutamate receptors84, October 1, 2014 ª2014 Elsevier Inc. 15
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because of the role they were thought
to play in neurological disorders such
as stroke, ischemia, or slowly progress-
ing neurodegenerative diseases. The
straightforward application of low-strin-
gency hybridization with probes based
on other neurotransmitter receptor pro-
teins was a fruitless endeavor, for rea-
sons which became clear after the
cloning of the first glutamate receptor
by Michael Hollmann in Steve’s labora-
tory. Michael chose the very laborious
approach known as ‘‘expression clon-
ing,’’ which relied on the detection of re-
ceptor currents (in this case, evoked by
the agonist kainic acid) following injec-
tion of appropriate RNAs into Xenopus
oocytes, which was a novel approach
that had been recently developed by
Ricardo Miledi. Armed with a library of
cDNAs prepared from rat brain tissue,
Hollmann’s persistent and sustained
effort chased a small, perhaps initially
unconvincing kainate-evoked depolariza-
tion through ever-smaller pools of unique
cDNAs, and ultimately yielded the first
iGluR subunit to be cloned, which they
named GluR-K1. We now refer to this
AMPA receptor subunit as GluA1, and
its cloning led to a tense race to the finish
within the Heinemann laboratory and
with other laboratories, most particularly
that of Peter Seeburg at the University
of Heidelberg, to clone other AMPA re-
ceptor subunits and the related kainate
and NMDA receptors. This initial cloning
feat was obviously a gold mine that led
to numerous secondary areas of explo-
ration and discovery. For example, the
precise topology of the receptor subunits
in the plasma membrane was an unex-
pected matter for debate. The shared
structural template for other ligand-gated
neurotransmitter receptors, nAChRs, and
GABAA receptors naturally led to the
expectation that iGluRs would be con-
structed on similar principles. This turned
out not to be the case; however, using a
set of opportune mutants of recombinant
receptors, Steve’s laboratory demon-
strated iGluRs only had three transmem-
brane domains plus a cytoplasm-facing
re-entrant membrane loop. The cloning
of iGluR subunit cDNAs also yielded an
ancillary surprise when it was discovered
by the Seeburg and Heinemann labora-
tories that cellular mechanisms exist to16 Neuron 84, October 1, 2014 ª2014 Elseviechange the encoded sequence of some
receptor subunit genes, now referred
to as RNA editing, which in the case of
AMPA and kainate receptors has pro-
found functional consequences. While
the stakes during and subsequent to
the iGluR cloning race were obviously
quite high, Steve appreciated this com-
petition not as a threat, but instead as a
compelling source of motivation and
occasional amusement, and in later
days the high drama and tension of
these pivotal times grew to mythological
proportions.
The cloning efforts led by the Heine-
mann laboratory also confirmed earlier
pharmacological studies that implicated
kainate receptors as a subfamily of
iGluRs distinct from AMPA receptors
(or ‘‘quisqualic receptors,’’ as they also
were known earlier), and therefore
signaled the end to the dysmorphic
appellation of ‘‘non-NMDA’’ or ‘‘AMPA/
kainate’’ receptors that was in common
use. Steve enthusiastically supported all
attempts from his fellow collaborators to
understand the functional relevance of
these newcomers. It soon appeared that
the gene-targeting approach in mice,
which was still in its infancy, was particu-
larly suited to decipher the mysteries of
this receptor family, because many con-
ventional approaches proved problem-
atic (and some, such as the development
of selective anti-subunit antibodies,
remain so). Knockout mice from all kai-
nate receptor subunits produced in
Steve’s laboratory finally revealed their
peculiar and unexpected roles in the
regulation of activity of hippocampal cir-
cuits. The newly cloned glutamate recep-
tors and these unique mouse models
were undeniably valuable resources
for many neurobiologists working on
mammalian synaptic function and plas-
ticity, and Steve Heinemann was exem-
plary in his commitment to making these
tools accessible to as many laboratories
as possible. The myriad of acknowledg-
ments in studies from scientific reports,
originating from laboratories all over the
world, make clear that his remarkable
generosity greatly contributed to the swift
progress in understanding neurotrans-
mitter receptors and synaptic mecha-
nisms over the last three decades. This
undoubtedly includes many new thera-
peutic avenues for pharmaceutical andr Inc.biotechnological companies to search
for cures in the treatment of ‘‘synaptopa-
thies’’ such as stroke, epilepsy, Parkin-
son’s and Alzheimer’s diseases, as well
as neuropsychiatric conditions. Steve’s
most recent work highlights the broad-
ness of his views and his continuous
interest in the mysteries of the normal
and diseased brain, from astrocytes
and oscillations in recognition memory
to nicotinic receptors in Alzheimer’s
disease.
In addition to leading his laboratory,
Steve was an active member of the
greater scientific community and received
a number of awards and honors for
his research accomplishments. Most
notably, he was elected president of
the Society for Neuroscience from
2005 to 2006. He was also a member
of the National Academy of Sciences,
the National Institute of Medicine, and
the American Academy of Arts & Sci-
ences. He received the Bristol-Myers
Squibb Distinguished Achievement in
Neuroscience Research Award and the
McKnight Award for Research. In 2010,
he was awarded the Julius Axelrod
Prize for exceptional achievements in
neuropharmacology and exemplary ef-
forts in mentoring young scientists. In
this regard, Steve leaves a wide-reach-
ing scientific legacy that includes not
only his seminal contributions to our
understanding of the molecular identity
and function of nicotinic cholinergic
and glutamate receptors, but also
shaping the course of neuroscience in
the US and the world during a time of
acute interest in all aspects of brain
function.
On a more personal level, the hundred-
plus ‘‘Heinemaniacs’’ who comprised
his laboratory over the many years of
its existence were challenged by the
free-wheeling nature and abundant
possibilities that were intrinsic to life
as a member of Steve’s team. He
created a uniquely anarchic environment
that fostered creative, competitive, and
rigorous science limited only by imagina-
tion. ‘‘Stevie’’ was a generous mentor
and colleague, a courageous man of
contagious energy and enthusiasm, and
an adventurous and bright scientist who
was always open for a spirited debate
about interpretation of data, research at
large, and the vagaries of success and
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away from the latter when principle was
involved, as was the case when, as the
incoming President of the Society for
Neuroscience, he helped to organize
a controversial ‘‘Dialogues Between
Neuroscience and Society’’ lecture by
the Dalai Lama at the 2005 annual
meeting. He was a natural storyteller
with an endless supply of entertaining
and occasionally absurd anecdotes
from his scientific and personal life,
many of them drawn from adventures
during his hiking trips and excursions
into the backcountry of Baja California
and farther afield. Steve appeared to us
at heart to be a rebel, fighting against au-
thority in its various forms with a sense of
amusement and mischievousness, evenwhen he himself was the authority in
question. As a nominee for President
of the Society for Neuroscience, for
example, he campaigned within the labo-
ratory for votes—for his rival. Steve epit-
omized the principle that, at its core, sci-
entific research should be a fun pursuit
as well as intellectually stimulating, and
he demonstrated by his actions that suc-
cess at the highest levels could be
achieved without compromising princi-
ples or losing sight of those most impor-
tant aspects of life. It is difficult now to
imagine the Salk Institute without Steve
Heinemann, but it is clear that his legacy
will continue to flow forward into the
future, a scientific manifestation of the
‘‘stream of knowledge’’ that famously bi-
sects the central courtyard of the SalkNeuronInstitute en route to the endless horizon
of the Pacific Ocean.
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